Summary & Overview
CPT 0578U: Merlin™ Test for Cutaneous Melanoma Risk Stratification
CPT code 0578U designates the Merlin™ Test, a proprietary PLA molecular diagnostic that evaluates gene expression in cutaneous melanoma to stratify risk of lymph node involvement and recurrence. As a single-manufacturer PLA code, 0578U identifies a specific 10-gene qPCR assay performed on FFPE tumor tissue and reported as low or high risk. Nationally, such PLA codes matter because they standardize billing and tracking for unique laboratory innovations used in cancer care and affect how payers and providers document and reimburse specialized molecular tests.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn the clinical context of the Merlin™ Test, where it is typically performed, and the implications of PLA coding for billing workflows. The publication summarizes payer coverage patterns and benchmarking where available, highlights relevant policy considerations for proprietary laboratory tests, and provides clinical context about test methodology and intended use in melanoma risk stratification. Data not available in the input are identified as such; the summary focuses on available national-level information rather than state-specific policies.
Billing Code Overview
CPT code 0578U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the Merlin™ Test from SkylineDx USA Inc. The Merlin™ Test evaluates cutaneous melanoma tissue for gene activity associated with risk of lymph node involvement and recurrence. The assay measures expression of 10 genes using real–time quantitative polymerase chain reaction (qPCR) on a formalin–fixed paraffin–embedded (FFPE) tumor sample and reports a result indicating low or high risk for nodal metastasis and recurrence.
Service type: Laboratory molecular diagnostic test (proprietary gene expression assay)
Typical site of service: Clinical laboratory or pathology/laboratory service associated with oncology or dermatopathology; specimen collected from outpatient dermatology or surgical oncology setting and processed in a certified laboratory.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a recently excised primary cutaneous melanoma undergoes pathologic staging. The surgical pathology report shows intermediate Breslow depth and/or other adverse features prompting assessment for risk of lymph node involvement and recurrence. The treating dermatologic surgeon or surgical oncologist requests the Merlin™ Test (0578U) on the formalin‑fixed paraffin‑embedded (FFPE) tumor block. The specimen is shipped to SkylineDx USA Inc.; the laboratory performs real‑time qPCR on a 10‑gene panel and reports a binary risk result (low vs high) that informs decisions about sentinel lymph node biopsy, postoperative surveillance intensity, and multidisciplinary care planning. Typical site of service includes an outpatient hospital laboratory or independent clinical reference laboratory; specimen collection and surgical excision occur in an ambulatory surgical center or hospital outpatient setting. Common modifiers applied to billing include 00 (default), 22 (increased procedural services), 52 (reduced services), and 53 (discontinued procedure) depending on reporting circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|